Title : Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRASG12R-mutant pancreatic ductal adenocarcinoma.

Pub. Date : 2021 Jun

PMID : 33405090






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 We conducted a biomarker-driven trial of selumetinib (KOSELUGO ; ARRY-142886), an orally active, allosteric mitogen-activated protein kinase 1 and 2 (MEK1/2) inhibitor, in pancreas cancer patients with somatic KRASG12R mutations. AZD 6244 mitogen-activated protein kinase 1 Homo sapiens